The prevalence of PFOs in the general population is approximately 25%. Patent foramen ovales are usually clinically silent, although they are associated with stroke.1,2 Only recently have large-scale data suggested a benefit of PFO closure for secondary stroke prevention. This AAN guideline updates previous guidelines, incorporating recent data on the effect of PFO closure and antithrombotic and antiplatelet therapy on stroke risk.
Dia A, Cifu AS, Shah AP. Management of Patients With a Patent Foramen Ovale With History of Stroke or TIA. JAMA. 2021;325(1):81–82. doi:10.1001/jama.2020.22176
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: